EFFECT OF HEPARIN ON PLASMA LIPID PARTITION IN MAN: STUDIES IN NORMAL PERSONS AND IN PATIENTS WITH CORONARY ATHEROSCLEROSIS, NEPHROSIS AND PRIMARY HYPERLIPEMIA
Authors: J HERZSTEIN, C I WANG, D ALDERSBERG
Journal: Annals of Internal Medicine (1954)

Article1 February 1954EFFECT OF HEPARIN ON PLASMA LIPID PARTITION IN MAN: STUDIES IN NORMAL PERSONS AND IN PATIENTS WITH CORONARY ATHEROSCLEROSIS, NEPHROSIS AND PRIMARY HYPERLIPEMIAJOSEPH HERZSTEIN, M.D., CHUN-I WANG, M.D., DAVID ADLERSBERG, M.D., F.A.C.P.JOSEPH HERZSTEIN, M.D., CHUN-I WANG, M.D., DAVID ADLERSBERG, M.D., F.A.C.P.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-40-2-290 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThis study is concerned with the effect of heparin on plasma lipid partition in man under normal and certain pathologic conditions. That heparin reduces the opacity of lipemic blood plasma has been demonstrated in several laboratories. While some observations have been made on individual plasma lipids after heparin administration,6-10comprehensive studies of plasma lipid partition in normal persons and in disturbances associated with lipemia are almost wholly lacking. In this investigation the effect of heparin on plasma lipids was observed in 25 subjects in four groups consisting of 10 normal men, five patients with coronary atherosclerosis, seven with nephrosis and...Bibliography1. AhrensKunkel EHHJ: The stabilization of serum lipid emulsions by serum phospholipids, J. Exper. Med. 19: 409, 1949. CrossrefGoogle Scholar2. AdlersbergSchaeferDrachman DLESR: Studies of hormonal control of serum lipid partition in man, J. Clin. Endocrinol. 11: 67, 1951. CrossrefGoogle Scholar3. SperrySchoenheimer WMR: A comparison of serum, heparinized plasma and oxalated plasma in regard to cholesterol content, J. Biol. Chem. 110: 655, 1935. CrossrefGoogle Scholar4. AdlersbergSobotka DH: Fat and vitamin A absorption in sprue and jejunoileitis, Gastroenterology 1: 357, 1943. Google Scholar5. MessingerPorosowski WJY: Influence of small doses of heparin on fat tolerance curves in vivo and in vitro, Proc. Soc. Exper. Biol. and Med. 82: 164, 1953. CrossrefMedlineGoogle Scholar6. BlockMannBarker WJFDNW: Effect of small doses of heparin in increasing the translucence of plasma during alimentary lipemia, Proc. Staff Meet., Mayo Clin. 26: 246, 1951. MedlineGoogle Scholar7. BlockBarkerMann WJNWFD: Effect of small doses of heparin in increasing the translucence of plasma during alimentary lipemia, Circulation 4: 674, 1952. CrossrefGoogle Scholar8. Van EckPetersMan WFJPEB: Significance of lactescence in blood serum, Metabolism 1: 383, 1952. MedlineGoogle Scholar9. KlatskinGordon GM: Relationship between relapsing pancreatitis and essential hyperlipemia, Am. J. Med. 12: 3, 1952. CrossrefMedlineGoogle Scholar10. BasuStewart DPCP: Effect of heparin on the plasma cholesterol, Edinburgh M. J. 57: 596, 1950. MedlineGoogle Scholar11. Hahn PF: Abolishment of alimentary lipemia following injection of heparin, Science 98: 17, 1943. CrossrefGoogle Scholar12. AndersonFawcett NGB: An anti-chylomicronemic substance produced by heparin, Proc. Soc. Exper. Biol. and Med. 74: 768, 1950. CrossrefMedlineGoogle Scholar13. WaldronFriedman JMMH: The relationship between anticoagulants and lipemia, Federation Proc. 7: 130, 1948. MedlineGoogle Scholar14. BrownBoyleAnfinsen RKECB: Purification and properties of lipemia clearing factor, Federation Proc. 2: 18, 1952. Google Scholar15. Swank RL: Changes in blood produced by a fat meal and by intravenous heparin, Am. J. Physiol. 164: 798, 1951. CrossrefMedlineGoogle Scholar16. Weld CB: Alimentary lipemia and heparin, Canad. M. A. J. 51: 579, 1944. Google Scholar17. AnfinsenBoyleBrown CBERK: The role of heparin in lipoprotein metabolism, Science 115: 583, 1952. CrossrefMedlineGoogle Scholar18. BrownKauffman RKDL: In vitro formation of lipemia clearing factor, Federation Proc. 12: 183, 1953. Google Scholar19. ChargaffZiffCohen EMSS: Studies on the chemistry of blood coagulation, J. Biol. Chem. 136: 257, 1940. CrossrefGoogle Scholar20. SwankLevy RLSW: Chylomicron dissolution. Dosage and site of action of heparin, Am. J. Physiol. 178: 208, 1952. CrossrefGoogle Scholar21. PalosKocsan LAC: New data on the physico-chemical properties of heparin, Experientia 7: 97, 1951. CrossrefMedlineGoogle Scholar22. SwankFranklinQuastel RLAEJH: Effects of fat meals and heparin on blood plasma composition as shown by paper chromatography, Proc. Soc. Exper. Biol. and Med. 75: 3, 1950. CrossrefMedlineGoogle Scholar23. SwankWilmot RLV: Chylomicra: their composition and their fate after intravenous injection of small amounts of heparin, Am. J. Physiol. 167: 403, 1951. CrossrefMedlineGoogle Scholar24. GrahamLyonGofmanJonesYankleySimontonWhite DMTPJWHBAJS: Blood lipids and human atherosclerosis. The influence of heparin upon lipoprotein metabolism, Circulation 4: 666, 1951. CrossrefMedlineGoogle Scholar25. NicholsFreemanShoreRubin AVNKBL: The interaction of "heparin active factor" and lipoproteins, Circulation 6: 457, 1952. Google Scholar26. Nikkilä EA: The effect of heparin on serum lipoproteins, Skandinav. J. Clin. and Lab. Invest. 4: 4, 1952. Google Scholar27. Nikkilä EA: Studies on the lipid-protein relationships in normal and pathological sera and the effect of heparin on serum lipoproteins, Skandinav. J. Clin. and Lab. Invest. 5: Suppl. 8, 1953. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication June 10, 1953.From the Departments of Medicine and Chemistry, Mt. Sinai Hospital. This investigation was supported in part by a research grant from the Division of Research Grants and Fellowships, National Institutes of Health, United States Public Health Service. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByThe Assay of Lipoprotein Lipase in Vivo and in VitroHeparin-activated lipase in diabetic, atherosclerotic and healthy subjectsThe clinical usage of heparinDie Wirkung wiederholter Heparininjektionen auf den Gesamtfett- und Cholesterinspiegel des Serums von gesunden RattenComparison of continuous long-term heparin and oral anticoagulant therapy in patients with severe angina pectorisRepository Heparin as an Antiatherogenic AgentNon-esterified fatty acids and lipoprotein lipase activity in patients with cirrhosis of the liverUntersuchungen �ber den intermedi�ren Fettstoffwechsel bei der ArteriosklerosePostprandial Lipemia in Health and in Ischemic Heart DiseaseALIMENTARY LIPÆMIA AND ISCHÆMIC HEART-DISEASEDie Lipoproteidlipase und ihre klinische BedeutungDie Lipoproteide des Blutserums und ihre klinische BedeutungKrankheiten der GefäßeCORONARY ARTERY DISEASEUntersuchungen zur Hyperlipid�mie beim nephrotischen SyndromClearing Factor Inhibitor in Human AtherosclerosisThe effect of heparin on the development of experimental atherosclerosisHeparin-Therapie und Klinik der idiopathischen hyperlipid�mischen XanthomatoseTHE EFFECTS OF ACUTE CARDIAC INFARCTION AND OF HEPARIN THERAPY ON THE LIPOPROTEINSBeiträge zur antilipämischen Wirkung des HeparinsBeiträge zur antilipämischen Wirkung des HeparinsMethoden zum Studium der ChylomikronenHeparin-Activated Clearing FactorEssential hyperlipemiaNeuere Ergebnisse der AtheroskleroseforschungESSENTIAL HYPERLIPÆMIAUntersuchungen �ber das Verhalten der Lipo- und Glykoproteide bei arteriographisch gesicherten ArteriosklerosenDie Wirkung von Heparin auf den Ablauf der experimentellen Nephritis-NephroseThe clinicopathologic meaning of the nephrotic syndrome 1 February 1954Volume 40, Issue 2Page: 290-306KeywordsBlood plasmaFellowshipsHeparinHospital medicineHyperlipidemiaLipidsMedical servicesPrevention, policy, and public healthResearch grantsStable coronary artery disease Issue Published: 1 February 1954 PDF DownloadLoading ...